Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
AA1SAbXjGnVLPSHK